Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Operating Income: 2022-2025

Historic Operating Income for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$885,260.

  • Addex Therapeutics' Operating Income rose 10.98% to -$885,260 in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.8 million, marking a year-over-year increase of 21.92%. This contributed to the annual value of -$3.1 million for FY2024, which is 25.40% down from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Operating Income is -$885,260, which was down 31.28% from -$674,315 recorded in Q1 2025.
  • Addex Therapeutics' 5-year Operating Income high stood at -$397,496 for Q1 2023, and its period low was -$21.3 million during Q4 2022.
  • Its 3-year average for Operating Income is -$958,483, with a median of -$835,549 in 2023.
  • Its Operating Income has fluctuated over the past 5 years, first surged by 96.14% in 2023, then crashed by 127.15% in 2024.
  • Over the past 4 years, Addex Therapeutics' Operating Income (Quarterly) stood at -$21.3 million in 2022, then skyrocketed by 96.14% to -$822,846 in 2023, then surged by 38.18% to -$508,692 in 2024, then rose by 10.98% to -$885,260 in 2025.
  • Its Operating Income stands at -$885,260 for Q2 2025, versus -$674,315 for Q1 2025 and -$508,692 for Q4 2024.